Gabriela Patilea-Vrana

7PUBLICATIONS
38CO-AUTHORS
Predictive and prognostic markersChemotherapyBiologically active moleculesPharmacogenomicsMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Apr 20, 2026
First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer.

|Oct 02, 2025
FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Early-Phase Trials Using Innovative Trial Designs and Biomarkers.

Olanrewaju O Okusanya, Gabriela I Patilea-Vrana, Anthony Sireci

|Aug 24, 2023
SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications.

Robert P Lyon, Mechthild Jonas, Christopher Frantz

|May 04, 2019
Quantifying Hepatic Enzyme Kinetics of (-)-∆9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC, through In Vitro Modeling.

Gabriela I Patilea-Vrana, Jashvant D Unadkat

|Dec 21, 2018
Hepatic Enzymes Relevant to the Disposition of (-)-∆9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC.

Gabriela I Patilea-Vrana, Olena Anoshchenko, Jashvant D Unadkat

|Aug 18, 2018
When Does the Rate-Determining Step in the Hepatic Clearance of a Drug Switch from Sinusoidal Uptake to All Hepatobiliary Clearances? Implications for Predicting Drug-Drug Interactions.

Gabriela I Patilea-Vrana, Jashvant D Unadkat

Pageof 2

Frequent Collaborators

1 joint publications

Robert P Lyon

1 joint publications

Mechthild Jonas

1 joint publications

Christopher Frantz

1 joint publications

Esther S Trueblood